Why the study?
How do clinical BNP assay measurements correlate with mass spectrometry measurements of circulating BNP fragments in patients with chronic heart failure?
How do clinical BNP assay measurements correlate with mass spectrometry measurements of circulating BNP fragments in patients with chronic heart failure?
Clinically measured BNP correlates best with degradation fragments rather than intact bioactive BNP 1-32, suggesting clinical assays predominantly measure biologically inactive fragments.
No takes yet. Share an insight, caveat, or question.
Clinical BNP assays may primarily detect inactive fragments; leaves open whether they reflect bioactive BNP in chronic HF.
Miller et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: